Literature DB >> 27760760

DR3 signaling modulates the function of Foxp3+ regulatory T cells and the severity of acute graft-versus-host disease.

Hidekazu Nishikii1,2, Byung-Su Kim1, Yasuhisa Yokoyama2, Yan Chen1,3, Jeanette Baker1, Antonio Pierini1, Maite Alvarez1, Melissa Mavers4, Kristina Maas-Bauer1, Yuqiong Pan1, Shigeru Chiba2, Robert S Negrin1.   

Abstract

CD4+Foxp3+ regulatory T cells (Treg) are a subpopulation of T cells, which regulate the immune system and enhance immune tolerance after transplantation. Donor-derived Treg prevent the development of lethal acute graft-versus-host disease (GVHD) in murine models of allogeneic hematopoietic stem cell transplantation. We recently demonstrated that a single treatment of the agonistic antibody to DR3 (death receptor 3, αDR3) to donor mice resulted in the expansion of donor-derived Treg and prevented acute GVHD, although the precise role of DR3 signaling in GVHD has not been elucidated. In this study, we comprehensively analyzed the immunophenotype of Treg after DR3 signal activation, demonstrating that DR3-activated Treg (DR3-Treg) had an activated/mature phenotype. Furthermore, the CD25+Foxp3+ subpopulation in DR3-Treg showed stronger suppressive effects in vivo. Prophylactic treatment of αDR3 to recipient mice expanded recipient-derived Treg and reduced the severity of GVHD, whereas DR3 activation in mice with ongoing GVHD further promoted donor T-cell activation/proliferation. These data suggest that the function of DR3 signaling was highly dependent on the activation status of the T cells. In conclusion, our data demonstrated that DR3 signaling affects the function of Treg and T-cell activation after alloantigen exposure in a time-dependent manner. These observations provide important information for future clinical testing using human DR3 signal modulation and highlight the critical effect of the state of T-cell activation on clinical outcomes after activation of DR3.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27760760      PMCID: PMC5159706          DOI: 10.1182/blood-2016-06-723783

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

1.  Genomic definition of multiple ex vivo regulatory T cell subphenotypes.

Authors:  Markus Feuerer; Jonathan A Hill; Karsten Kretschmer; Harald von Boehmer; Diane Mathis; Christophe Benoist
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-15       Impact factor: 11.205

2.  Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation.

Authors:  Taylor H Schreiber; Dietlinde Wolf; Matthew S Tsai; Jackie Chirinos; Vadim V Deyev; Louis Gonzalez; Thomas R Malek; Robert B Levy; Eckhard R Podack
Journal:  J Clin Invest       Date:  2010-09-20       Impact factor: 14.808

3.  In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation.

Authors:  Vu H Nguyen; Robert Zeiser; Daniel L Dasilva; Daisy S Chang; Andreas Beilhack; Christopher H Contag; Robert S Negrin
Journal:  Blood       Date:  2006-11-09       Impact factor: 22.113

4.  Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease.

Authors:  Antonio Pierini; Lucrezia Colonna; Maite Alvarez; Dominik Schneidawind; Hidekazu Nishikii; Jeanette Baker; Yuqiong Pan; Mareike Florek; Byung-Su Kim; Robert S Negrin
Journal:  J Immunol       Date:  2015-05-20       Impact factor: 5.422

5.  Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95.

Authors:  A M Chinnaiyan; K O'Rourke; G L Yu; R H Lyons; M Garg; D R Duan; L Xing; R Gentz; J Ni; V M Dixit
Journal:  Science       Date:  1996-11-08       Impact factor: 47.728

6.  Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells.

Authors:  Angela M Thornton; Patricia E Korty; Dat Q Tran; Elizabeth A Wohlfert; Patrick E Murray; Yasmine Belkaid; Ethan M Shevach
Journal:  J Immunol       Date:  2010-02-24       Impact factor: 5.422

7.  Third-party CD4+ invariant natural killer T cells protect from murine GVHD lethality.

Authors:  Dominik Schneidawind; Jeanette Baker; Antonio Pierini; Corina Buechele; Richard H Luong; Everett H Meyer; Robert S Negrin
Journal:  Blood       Date:  2015-03-20       Impact factor: 22.113

8.  Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.

Authors:  Claudio G Brunstein; Jeffrey S Miller; Qing Cao; David H McKenna; Keli L Hippen; Julie Curtsinger; Todd Defor; Bruce L Levine; Carl H June; Pablo Rubinstein; Philip B McGlave; Bruce R Blazar; John E Wagner
Journal:  Blood       Date:  2010-10-15       Impact factor: 22.113

9.  The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases.

Authors:  Françoise Meylan; Todd S Davidson; Erin Kahle; Michelle Kinder; Krishika Acharya; Dragana Jankovic; Virgilio Bundoc; Marcus Hodges; Ethan M Shevach; Andrea Keane-Myers; Eddie C Y Wang; Richard M Siegel
Journal:  Immunity       Date:  2008-06-19       Impact factor: 31.745

10.  Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation.

Authors:  Lei Fang; Becky Adkins; Vadim Deyev; Eckhard R Podack
Journal:  J Exp Med       Date:  2008-04-14       Impact factor: 14.307

View more
  21 in total

Review 1.  Current approaches to prevent and treat GVHD after allogeneic stem cell transplantation.

Authors:  Betty Ky Hamilton
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy.

Authors:  Robert Zeiser; Bruce R Blazar
Journal:  N Engl J Med       Date:  2017-11-30       Impact factor: 91.245

3.  Use of Post-transplant Cyclophosphamide Treatment to Build a Tolerance Platform to Prevent Liquid and Solid Organ Allograft Rejection.

Authors:  Casey O Lightbourn; Dietlinde Wolf; Sabrina N Copsel; Ying Wang; Brent J Pfeiffer; Henry Barreras; Cameron S Bader; Krishna V Komanduri; Victor L Perez; Robert B Levy
Journal:  Front Immunol       Date:  2021-03-02       Impact factor: 7.561

4.  Regulation of murine NK cell exhaustion through the activation of the DNA damage repair pathway.

Authors:  Maite Alvarez; Federico Simonetta; Jeanette Baker; Antonio Pierini; Arielle S Wenokur; Alyssa R Morrison; William J Murphy; Robert S Negrin
Journal:  JCI Insight       Date:  2019-06-18

5.  Very Low Numbers of CD4+ FoxP3+ Tregs Expanded in Donors via TL1A-Ig and Low-Dose IL-2 Exhibit a Distinct Activation/Functional Profile and Suppress GVHD in a Preclinical Model.

Authors:  Sabrina Copsel; Dietlinde Wolf; Brandon Kale; Henry Barreras; Casey O Lightbourn; Cameron S Bader; Warren Alperstein; Norman H Altman; Krishna V Komanduri; Robert B Levy
Journal:  Biol Blood Marrow Transplant       Date:  2018-05-08       Impact factor: 5.742

6.  Impaired bone marrow B-cell development in mice with a bronchiolitis obliterans model of cGVHD.

Authors:  Oleg V Kolupaev; Trisha A Dant; Hemamalini Bommiasamy; Danny W Bruce; Kenneth A Fowler; Stephen L Tilley; Karen P McKinnon; Stefanie Sarantopoulos; Bruce R Blazar; James M Coghill; Jonathan S Serody
Journal:  Blood Adv       Date:  2018-09-18

Review 7.  Analysis of therapeutic potential of preclinical models based on DR3/TL1A pathway modulation (Review).

Authors:  Yunhong Yu; Peng Jiang; Pan Sun; Na Su; Fangzhao Lin
Journal:  Exp Ther Med       Date:  2021-05-02       Impact factor: 2.447

8.  Immune phenotype of the CD4+ T cells in the aged lymphoid organs and lacrimal glands.

Authors:  Claudia M Trujillo-Vargas; Kelsey E Mauk; Humberto Hernandez; Rodrigo G de Souza; Zhiyuan Yu; Jeremias G Galletti; Jana Dietrich; Friedrich Paulsen; Cintia S de Paiva
Journal:  Geroscience       Date:  2022-03-12       Impact factor: 7.713

Review 9.  Immune regulation in hematopoietic cell transplantation.

Authors:  Robert S Negrin
Journal:  Bone Marrow Transplant       Date:  2019-08       Impact factor: 5.483

Review 10.  Regulatory T Cells in GVHD Therapy.

Authors:  Wen-Wen Guo; Xiu-Hua Su; Ming-Yang Wang; Ming-Zhe Han; Xiao-Ming Feng; Er-Lie Jiang
Journal:  Front Immunol       Date:  2021-06-18       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.